/PRNAF
PRNAF Stock - Alterity Therapeutics Limited
Healthcare|BiotechnologyOTC
$0.01+0.00%
+$0.00 (+0.00%) • Dec 19
61
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.27
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.01
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PRNAF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.01 – $0.01
TARGET (TP)$0.01
STOP LOSS$0.01
RISK/REWARD1:-1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.05
52W High$0.01
52W Low$0.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $5.44M | $4.02M | $3.92M | $5.12M | $4.34M |
| Gross Profit | $5.31M | $3.80M | $3.81M | $5.07M | $3.98M |
| Gross Margin | 97.7% | 94.7% | 97.4% | 98.9% | 91.7% |
| Operating Income | $-14,574,286 | $-19,601,709 | $-14,606,738 | $-15,500,831 | $-15,176,317 |
| Net Income | $-12,147,828 | $-19,123,464 | $-13,806,515 | $-12,847,061 | $-15,309,353 |
| Net Margin | -223.4% | -475.8% | -352.5% | -250.7% | -352.8% |
| EPS | $-0.00 | $-0.01 | $-0.01 | $-0.01 | $-0.01 |
Company Overview
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
PRNAFBeat Rate
67%
Last 9 quarters
Avg Surprise
-501.2%
EPS vs Estimate
Beats / Misses
6/3
Last 12 quarters
Latest EPS
$-0.00
Q3 2025
EPS Surprise History
Q4 21
No data
Q3 22
+77.2%
$-0.00vs$-0.00
Q4 22
+39.2%
$-0.00vs$-0.00
Q3 23
-554.2%
$-0.00vs$-0.00
Q2 24
+713.6%
$0.00vs$-0.00
Q3 24
-4872.7%
$-0.01vs$-0.00
Q1 25
+17.9%
$-0.00vs$-0.00
Q3 25
+75.8%
$-0.00vs$-0.00
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 28, 2025 | $-0.00 | $-0.00 | +75.8% | ✓ BEAT |
Q1 2025 | Feb 28, 2025 | $-0.00 | $-0.00 | +17.9% | ✓ BEAT |
Q3 2024 | Aug 29, 2024 | $-0.00 | $-0.01 | -4872.7% | ✗ MISS |
Q2 2024 | Apr 30, 2024 | $-0.00 | $0.00 | +713.6% | ✓ BEAT |
Q3 2023 | Aug 31, 2023 | $-0.00 | $-0.00 | -554.2% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | $-0.00 | $-0.00 | +39.2% | ✓ BEAT |
Q3 2022 | Jul 22, 2022 | $-0.00 | $-0.00 | +77.2% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | — | $-0.00 | — | — |
Q3 2021 | Sep 2, 2021 | $-0.00 | $-0.00 | +59.3% | ✓ BEAT |
Q2 2021 | Apr 29, 2021 | — | $-0.00 | — | — |
Q3 2020 | Aug 31, 2020 | — | $-0.01 | — | — |
Q1 2020 | Feb 27, 2020 | — | $-0.00 | — | — |
Q3 2019 | Aug 30, 2019 | $-0.00 | $-0.01 | -67.2% | ✗ MISS |
Q4 2018 | Dec 31, 2018 | — | $-0.01 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.01 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.01 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.01 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-0.00 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.01 | — | — |
Q4 2015 | Dec 31, 2015 | — | $-0.00 | — | — |
Latest News
Loading news...
Frequently Asked Questions about PRNAF
What is PRNAF's current stock price?
Alterity Therapeutics Limited (PRNAF) is currently trading at $0.01 per share. The stock has moved +0.00% today.
What is the analyst price target for PRNAF?
No analyst price targets are currently available for this stock.
What sector is Alterity Therapeutics Limited in?
Alterity Therapeutics Limited operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is PRNAF's market cap?
Alterity Therapeutics Limited has a market capitalization of $0.07 billion, making it a small-cap company.
Does PRNAF pay dividends?
No, Alterity Therapeutics Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATGGF
Actinogen Medical Limited
$0.04
Mkt Cap: $0.1B
BSEM
BioStem Technologies, Inc.
$4.24
Mkt Cap: $0.1B
CLTEF
Calliditas Therapeutics AB (publ)
$0.55
Mkt Cap: $0.0B
HBPCF
Helix BioPharma Corp.
$1.73
Mkt Cap: $0.1B
IUGNF
Imugene Limited
$0.22
Mkt Cap: $0.1B
MSCLF
Satellos Bioscience Inc.
$0.48
Mkt Cap: $0.1B
NICXF
Nicox S.A.
$0.30
Mkt Cap: $0.0B
PHYOF
IXICO plc
$0.07
Mkt Cap: $0.0B
PSYBF
PsyBio Therapeutics Corp.
$0.00
Mkt Cap: $0.0B
SPHRY
Starpharma Holdings Limited
$2.20
Mkt Cap: $0.1B
Explore stocks similar to PRNAF for comparison